Oncodesign: 1st half of 2015 total revenue increases 93%

Regulatory News:

ONCODESIGN (Paris:ALONC), a biotech serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment, today announces its revenue and cash position at June 30, 2015.

Experimentation: further buoyant momentum

Over the 1^st half of 2015, Experimentation revenue was up +77%, reaching €4.57m.

Within the same period, new orders also continued to record strong growth (+78%), and amounted to €5.38m over the half-year. This trend was notably driven by buoyant growth in Europe (excluding France) and North America, which accounted for 58% and 21% of total orders respectively.

These performances represent a new record high for a 6-month period, and are the result of the strengthening of Oncodesign’s teams in recent months with 10 additional staff members hired in Experimentation during the 1^st half of 2015.

Oncodesign thus ended the 1^st half of 2015 with an order book worth €4.3m, up +23% compared with December 31, 2014, which augurs well for continued buoyant momentum over the 2^nd half of 2015 and a further increase in market share.

Discovery: growth of +168% sustained by the payment received from UCB

Over the first six months of the year, revenue from research collaboration was multiplied by over 2.5 and totaled €1.42m, compared with €0.53m for the 1^st half of 2014.

This revenue figure reflects both the ongoing partnerships with Ipsen, Sanofi and UCB, and the payment made by the latter in June 2015 after it exercised its option to acquire a worldwide license for Oncodesign’s highly specific inhibitors of a kinase selected by UCB in the field of neurological diseases.

Cash position of €9.4m, cash burn limited to €0.8m over the half-year

At June 30, 2015, Oncodesign had a cash position of €9.4m. Cash burn over the 1^st half of 2015 thus amounted to only €0.8m, illustrating the financial solidity of Oncodesign’s business model.

"This first half of 2015 lays witness to the high level of confidence our technological platforms benefit from on the one hand, and the buoyant growth momentum we have been able to generate by strengthening our sales teams, notably in North America on the other. We now need to continue following this development strategy by continuously providing innovative technologies and by achieving further major milestones by the end of 2015. We thus expect to carry out our first experimentation studies directly in North America or take our first proprietary molecule resulting from our Nanocyclix technology in the field of PET tracers in oncology into the clinical phase. Following the recent successes achieved within the framework of our partnership with UCB, this further enhances our ambitions and Nanocyclix’s potential in discovering new kinase inhibitors,” concludes Philippe Genne, Chairman, CEO and founder of Oncodesign.

Next financial publication:

Results for the 1^st half of 2015 are expected to be published on Tuesday September 15, 2015 (after market)

About Oncodesign: www.oncodesign.com

Founded 20 years ago by Dr. Philippe Genne, the Company’s CEO and Chairman, ONCODESIGN is a biotechnology company that maximizes the pharmaceutical industry’s chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment. Backed by unique experience acquired through more than 600 clients, including the world’s largest pharmaceutical companies, and relying on a comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modeling and medical imaging, ONCODESIGN is able to predict and identify for every molecule, very upstream, its therapeutic use and its potential to become an efficient drug. Applied to kinase inhibitors, molecules that represent a market estimated at over 40 billion dollars in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D investments, ONCODESIGN’s technology has already enabled the targeting of 7 promising molecules with substantial therapeutic potential, in oncology and elsewhere, and the signing of partnerships, potentially worth €350 million in upfront payments should predefined milestones be reached, with pharmaceutical groups Sanofi, Ipsen and UCB. Based in Dijon, France, in the heart of the town’s university and hospital hub, ONCODESIGN has 85 staff.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150721006193/en/